TRANSCENTA-B(06628)

2.350-0.020-0.84%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Transcenta Holding Limited's (HKG:6628) largest shareholders are retail investors who were rewarded as market cap surged HK$130m last week
  Simply Wall St. · 01-08
  Transcenta Holding Limited's (HKG:6628) largest shareholders are retail investors who were rewarded as market cap surged HK$130m last week
- Transcenta Grants Two Million Award Shares
  MT Newswires Live · 2025-12-29
  Transcenta Grants Two Million Award Shares
- TRANSCENTA-B (06628) Grants 2 Million Shares as Incentive Awards
  Stock News · 2025-12-29
  TRANSCENTA-B (06628) Grants 2 Million Shares as Incentive Awards
- Transcenta Holding Grants 2 Million Award Shares Under Share Incentive Scheme
  Reuters · 2025-12-29
  Transcenta Holding Grants 2 Million Award Shares Under Share Incentive Scheme
- BRIEF-Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.
  Reuters · 2025-12-29
  BRIEF-Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.
- TRANSCENTA-B (06628) Enters Strategic Collaboration and Non-Exclusive Technology License Agreement with EirGenix
  Stock News · 2025-12-29
  TRANSCENTA-B (06628) Enters Strategic Collaboration and Non-Exclusive Technology License Agreement with EirGenix
- Transcenta Therapeutics Announces Strategic Collaboration and Non-Exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
  THOMSON REUTERS · 2025-12-29
  Transcenta Therapeutics Announces Strategic Collaboration and Non-Exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
- Transcenta Holding Ltd - Announces Collaboration and Non-Exclusive Licensing Agreement With Eirgenix Inc.
  THOMSON REUTERS · 2025-12-29
  Transcenta Holding Ltd - Announces Collaboration and Non-Exclusive Licensing Agreement With Eirgenix Inc.
- Transcenta - Grants Eirgenix Non-Exclusive License for Its Highly Intensified Continuous Bioprocessing Platform
  THOMSON REUTERS · 2025-12-29
  Transcenta - Grants Eirgenix Non-Exclusive License for Its Highly Intensified Continuous Bioprocessing Platform
- Transcenta Grants EirGenix License for HiCB Biomanufacturing Platform
  Reuters · 2025-12-29
  Transcenta Grants EirGenix License for HiCB Biomanufacturing Platform
- Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 10,000 Shares at HK$2.14 per Share
  Stock News · 2025-12-22
  Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 10,000 Shares at HK$2.14 per Share
- Transcenta Therapeutics Presents Updated Efficacy Data From the Phase I/Ii Transtar102 Trial of Osemitamab Plus Nivolumab and Capox in First-Line G/Gej Cancer at Esmo Asia
  THOMSON REUTERS · 2025-12-05
  Transcenta Therapeutics Presents Updated Efficacy Data From the Phase I/Ii Transtar102 Trial of Osemitamab Plus Nivolumab and Capox in First-Line G/Gej Cancer at Esmo Asia
- TRANSCENTA-B (06628): Updated Efficacy Data of Osemitamab Triple Therapy for First-Line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma Presented at ESMO Asia
  Stock News · 2025-12-05
  TRANSCENTA-B (06628): Updated Efficacy Data of Osemitamab Triple Therapy for First-Line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma Presented at ESMO Asia
- Transcenta (Stock Code: 6628) Releases Updated Efficacy Data for Osemitamab Combination in First-Line G/GEJ Cancer
  Bulletin Express · 2025-12-05
  Transcenta (Stock Code: 6628) Releases Updated Efficacy Data for Osemitamab Combination in First-Line G/GEJ Cancer
- Transcenta Reports Promising Phase I/II Trial Results for Osemitamab in G/GEJ Cancer
  Reuters · 2025-12-05
  Transcenta Reports Promising Phase I/II Trial Results for Osemitamab in G/GEJ Cancer
- Transcenta (06628) Releases November 2025 Monthly Return on Share Capital and Incentive Schemes
  Bulletin Express · 2025-12-04
  Transcenta (06628) Releases November 2025 Monthly Return on Share Capital and Incentive Schemes
- Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 20,000 Shares at HK$2.5 Each
  Stock News · 2025-11-25
  Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 20,000 Shares at HK$2.5 Each
- TRANSCENTA-B (06628) Grants 200,000 Award Shares and 800,000 Share Options
  Stock News · 2025-11-20
  TRANSCENTA-B (06628) Grants 200,000 Award Shares and 800,000 Share Options
- Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 34,000 Shares at HK$2.86 Each
  Stock News · 2025-11-13
  Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 34,000 Shares at HK$2.86 Each
- TRANSCENTA-B (06628) Appoints EY as New Auditor
  Stock News · 2025-11-12
  TRANSCENTA-B (06628) Appoints EY as New Auditor
Company Profile
Company Name
TRANSCENTA-B
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.transcenta.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Transcenta Holding Ltd is a investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company also provides contract development and manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.

1D
5D
Day
Week
Month

Loading ...

High

2.410

Open

2.380

Volume%

0.44

Low

2.330

2.370

T/O Rate

0.07%

To The Moon

TRANSCENTA-B(06628)

Company Profile

Most Discussed